# Biotricity Inc. (BTCY)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/biotricity-inc/ JSON: https://steadybase.io/company/biotricity-inc.json Checked Nov 10, 2026. Latest filing read: Aug 19, 2026.

## Company

- Legal name: BIOTRICITY INC.
- Ticker: BTCY (OTC)
- SEC CIK: 0001630113
- Industry: Surgical & Medical Instruments & Apparatus (SIC 3841)
- Headquarters: Redwood City, CA
- Fiscal year ends: March 31
- SEC filer category: Non-accelerated filer<br>Smaller reporting company
- Website: biotricity.com
- LinkedIn: https://www.linkedin.com/company/biotricity-measuring-vitals
- Next earnings date: Nov 14, 2026 (estimated from past 8-K timing)

## Key facts

- Revenue: $16.0M for the fiscal year ended Mar 31, 2026 (10-K filed Jul 14, 2026). Source: https://www.sec.gov/Archives/edgar/data/1630113/000149315226033207/0001493152-26-033207-index.html
- Operating income: $1.7M for the fiscal year ended Mar 31, 2026 (10-K filed Jul 14, 2026). Source: https://www.sec.gov/Archives/edgar/data/1630113/000149315226033207/0001493152-26-033207-index.html
- Net income: -$2.4M for the fiscal year ended Mar 31, 2026 (10-K filed Jul 14, 2026). Source: https://www.sec.gov/Archives/edgar/data/1630113/000149315226033207/0001493152-26-033207-index.html
- SG&A: $8.5M for the fiscal year ended Mar 31, 2026 (10-K filed Jul 14, 2026). Source: https://www.sec.gov/Archives/edgar/data/1630113/000149315226033207/0001493152-26-033207-index.html
- Employees: 46 as of Mar 31, 2026, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1630113/000149315226033207/form10-k.htm
- Shares outstanding: 19,914,003 as of Aug 19, 2026 (10-Q filed Aug 19, 2026). Source: https://www.sec.gov/Archives/edgar/data/1630113/000149315226039209/0001493152-26-039209-index.html
- Auditor: Srco Professional Corporation, Richmond Hill, Ontario, Canada, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1630113/000149315226033207/form10-k.htm

## Business

Biotricity Inc. (the “Company”, “Biotricity”, “we”, “us”, “our”) is a medical technology company focused on biometric data monitoring solutions. Our aim is to deliver innovative, remote monitoring solutions to the medical, healthcare, and consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. We approach the diagnostic side of remote patient monitoring by applying innovation within existing business models where reimbursement is established.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1630113/000149315226033207/form10-k.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Mar 31, 2026 | $16.0M | $1.7M | -$2.4M | $8.5M |
| Mar 31, 2025 | $13.8M | -$2.4M | -$8.4M | $10.9M |
| Mar 31, 2024 | $12.1M | -$8.8M | -$14.1M | $14.6M |
| Mar 31, 2023 | $9.6M | -$15.4M | -$18.7M | $17.6M |
| Mar 31, 2022 | $7.7M | -$16.7M | -$29.1M | $18.6M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/biotricity-inc.json

## Officers and directors

- Waqaas Al-Siddiq, President, Chief Executive Officer and Chairman of the Board of Directors. Source: 10-K filed Jul 14, 2026, https://www.sec.gov/Archives/edgar/data/1630113/000149315226033207/form10-k.htm
- John Ayanoglou, Chief Financial Officer. LinkedIn: https://www.linkedin.com/in/johnayanoglou. Source: 10-K filed Jul 14, 2026, https://www.sec.gov/Archives/edgar/data/1630113/000149315226033207/form10-k.htm
- David A. Rosa, Director (Independent). Source: 10-K filed Jul 14, 2026, https://www.sec.gov/Archives/edgar/data/1630113/000149315226033207/form10-k.htm
- Jainal Bhuiyan, Director. Source: 10-K filed Jul 14, 2026, https://www.sec.gov/Archives/edgar/data/1630113/000149315226033207/form10-k.htm
- Ron McClurg, Director (Independent). Source: 10-K filed Jul 14, 2026, https://www.sec.gov/Archives/edgar/data/1630113/000149315226033207/form10-k.htm
- Ronald McClurg, Director. Source: 10-K filed Jul 14, 2026, https://www.sec.gov/Archives/edgar/data/1630113/000149315226033207/form10-k.htm

## Recent 8-K events

- Sep 28, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1630113/000149315226044407/form8-k.htm
- May 1, 2026: Item 1.01, Entry into a material definitive agreement; Item 3.02, Unregistered sales of equity securities; Item 5.03, Amendments to articles or bylaws; change in fiscal year; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1630113/000149315226020939/form8-k.htm
- Feb 18, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1630113/000149315226007369/form8-k.htm
- Nov 18, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1630113/000149315225024061/form8-k.htm
- Feb 24, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1630113/000149315225007938/form8-k.htm
- Nov 20, 2024: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1630113/000149315224046908/form8-k.htm
- Aug 16, 2024: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/1630113/000149315224032861/form8-k.htm
- Aug 7, 2024: Item 3.01, Notice of delisting or failure to meet listing standards. Source: https://www.sec.gov/Archives/edgar/data/1630113/000149315224030615/form8-k.htm
- Aug 1, 2024: Item 3.01, Notice of delisting or failure to meet listing standards. Source: https://www.sec.gov/Archives/edgar/data/1630113/000149315224029939/form8-k.htm
- Jul 16, 2024: Item 3.02, Unregistered sales of equity securities; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1630113/000149315224028050/form8-k.htm

## Latest filings

- 8-K filed Sep 28, 2026: https://www.sec.gov/Archives/edgar/data/1630113/000149315226044407/form8-k.htm
- 10-K filed Jul 14, 2026: https://www.sec.gov/Archives/edgar/data/1630113/000149315226033207/form10-k.htm
- 10-Q filed Aug 19, 2026: https://www.sec.gov/Archives/edgar/data/1630113/000149315226039209/form10-q.htm
- DEF 14A filed Aug 5, 2024: https://www.sec.gov/Archives/edgar/data/1630113/000149315224030135/formdef14a.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/